# A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

Source: https://onco.cc/trials/nct04529772/  
OnCo record `nct04529772` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Acalabrutinib, Prednisone, Rituximab in diffuse large b-cell lymphoma, run by Acerta Pharma BV, active and no longer recruiting.

## Summary

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) is a phase 3 interventional study registered as NCT04529772 by Acerta Pharma BV, with 611 participants enrolled, started 2020-10-08 and due to reach its primary completion in 2027-02-22. Interventions recorded: acalabrutinib, placebo, Prednisone, Rituximab, Cyclophosphamide. Conditions listed: Diffuse Large B-Cell Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04529772
- Phase: 3
- Setting: Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects ≤75 Years With Previously Untreated Non-GCB DLBCL
- Sponsor: Acerta Pharma BV
- Enrolled: 611

## Sources

- ClinicalTrials.gov NCT04529772: https://clinicaltrials.gov/study/NCT04529772

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- drugs: [Acalabrutinib](https://onco.cc/drugs/acalabrutinib/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Prednisone](https://onco.cc/drugs/prednisone/), [Rituximab](https://onco.cc/drugs/rituximab/), [Vincristine](https://onco.cc/drugs/vincristine/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct04529772.json